Across TCGA pan-cancer cohorts, LORICRIN mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LORICRIN data layer compared with 20 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LORICRIN mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LORICRIN expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC are the cancer types where LORICRIN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	II,III,IV	0.951	0.852	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: LORICRIN tumor-vs-normal RNA expression · all LORICRIN data types